ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $33.07 million. The enterprise value is $36.56 million.
Important Dates
The last earnings date was Tuesday, March 3, 2026, after market close.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 25.44 million shares outstanding. The number of shares has increased by 72.25% in one year.
| Current Share Class | 24.71M |
| Shares Outstanding | 25.44M |
| Shares Change (YoY) | +72.25% |
| Shares Change (QoQ) | +6.35% |
| Owned by Insiders (%) | 19.29% |
| Owned by Institutions (%) | 3.52% |
| Float | 19.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.91 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.41, with a Debt / Equity ratio of 0.26.
| Current Ratio | 0.41 |
| Quick Ratio | 0.12 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.20 |
Financial Efficiency
Return on equity (ROE) is -119.49% and return on invested capital (ROIC) is -43.21%.
| Return on Equity (ROE) | -119.49% |
| Return on Assets (ROA) | -31.25% |
| Return on Invested Capital (ROIC) | -43.21% |
| Return on Capital Employed (ROCE) | -48.00% |
| Weighted Average Cost of Capital (WACC) | 6.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$416,240 |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $24,154 in taxes.
| Income Tax | 24,154 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +105.91% in the last 52 weeks. The beta is 0.27, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | +105.91% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 37.68 |
| Average Volume (20 Days) | 54,089 |
Short Selling Information
The latest short interest is 246,701, so 0.97% of the outstanding shares have been sold short.
| Short Interest | 246,701 |
| Short Previous Month | 247,742 |
| Short % of Shares Out | 0.97% |
| Short % of Float | 1.24% |
| Short Ratio (days to cover) | 4.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.15M |
| Pretax Income | -8.35M |
| Net Income | -7.91M |
| EBITDA | -7.13M |
| EBIT | -7.15M |
| Earnings Per Share (EPS) | -$0.39 |
Full Income StatementBalance Sheet
The company has $745,834 in cash and $3.47 million in debt, with a net cash position of -$2.73 million or -$0.11 per share.
| Cash & Cash Equivalents | 745,834 |
| Total Debt | 3.47M |
| Net Cash | -2.73M |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | 13.30M |
| Book Value Per Share | 0.46 |
| Working Capital | -3.66M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.99M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.99M |
| FCF Per Share | -$0.12 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
